Odyssey Therapeutics, Inc. — Form 8-K
Filed October 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Odyssey announced completed Phase 2a induction results for OD-001 (oral RIPK2 scaffolding inhibitor) in 56 moderate-to-severe ulcerative colitis patients. At 20 mg BID (n=41), clinical remission was 27%, clinical response 61%, symptomatic remission 49%, with significant reductions in inflammatory biomarkers (hsCRP, neutrophils) and favorable safety (no SAEs, serious infections, or drug-related discontinuations). Transcriptomic analyses confirmed on-target RIPK2 pathway inhibition. Company advancing OD-001 into Phase 2b monotherapy and Phase 2a vedolizumab combination trials with topline results expected H2 2027.
Why this rating
Positive Phase 2 PoC in lead program validates mechanism and supports late-stage trials. OD-001 represents ~40-50% of pipeline; efficacy data, though open-label, strengthens confidence. Advancement timeline and safety profile de-risk clinical development. Relative to $484M asset base, clinical validation is material but not transformational without Phase 2b/3 success.
Tradability signal
NO TRADE
No trade: positive news with only -2.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.42% over 4 hrs, n=214). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $17.42 | +10 min · unknown $17.28 ▼ 0.80% | +30 min · unknown $18.19 ▲ 4.42% | +1 hr · unknown $18.62 ▲ 6.89% | +4 hrs · unknown $19.53 ▲ 12.11% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.